Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 376 - 400 of 14833 in total
Maralixibat (also known as SHP625, LUM001, and lopixibat) is an ileal bile acid transporter inhibitor, like odevixibat.[A236823,A239249,L38834] Maralixibat is indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome. Previously, patients with cholestatic pruritus associated with Alagille syndrome were treated with antihistamines, rifampin, ursodeoxycholic acid, cholestyramine, naltrexone, and...
Approved
Investigational
Matched Iupac: … -7-(dimethylamino)-4-hydroxy-1,1-dioxo-2,3,4,5-tetrahydro-1lambda6-benzothiepin-5-yl]phenoxy}methyl)phenyl
Matched Description: … Maralixibat (also known as SHP625, LUM001, and lopixibat) is an ileal bile acid transporter inhibitor ... [A239249] Surgical interventions such as partial external bile diversion and ileal exclusion have also ... were treated with antihistamines, [rifampin], [ursodeoxycholic acid], [cholestyramine], [naltrexone], and
Matched Categories: … Bile and Liver Therapy ... Alimentary Tract and Metabolism …
Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment.
Approved
Matched Iupac: … (3-{[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl …
Matched Description: … It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment …
Matched Categories: … Aprepitant and Prodrugs …
Acetylcysteine is an antioxidant and glutathione inducer indicated for mucolytic therapy and the treatment of acetaminophen overdose.[L31378,L31383,L31388,L31478] Acetylcysteine has also been studied for a wide variety of off-label indications with mixed results.[A228158,A228163,A228168] Acetylcysteine was granted FDA approval on 14 September 1963.
Approved
Investigational
Matched Description: … Acetylcysteine is an antioxidant and glutathione inducer indicated for mucolytic therapy and the treatment …
Matched Mixtures name: … Levomefolate Calcium Acetylcysteine and Mecobalamin Algal ... Levomefolate Calcium, Acetylcysteine, Mecobalamin and Algal …
Matched Categories: … Cough and Cold Preparations ... Amino Acids, Peptides, and Proteins …
A sulfur containing essential amino acid that is important in many body functions. It is a chelating agent for heavy metals.
Approved
Nutraceutical
Matched Mixtures name: … Aminosyn II and Dextrose ... Aminosyn II and Dextrose ... Men's Biomultiple Vitamin and Mineral Supplement …
Matched Categories: … Amino Acids, Peptides, and Proteins …
A non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain tissue. It is biosynthesized from aspartic acid and ammonia by asparagine synthetase. (From Concise Encyclopedia Biochemistry and Molecular Biology, 3rd ed)
Approved
Investigational
Nutraceutical
Matched Description: … (From Concise Encyclopedia Biochemistry and Molecular Biology, 3rd ed) ... It is biosynthesized from aspartic acid and ammonia by asparagine synthetase. ... A non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows this agent to...
Approved
Illicit
Matched Description: … Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity ... [A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical ... [A174367] Phentermine was FDA approved for short-term weight management in 1959 and it became widely …
Matched Categories: … Alimentary Tract and Metabolism ... phentermine and topiramate …
A second-line antitubercular agent that inhibits mycolic acid synthesis. It also may be used for treatment of leprosy. (From Smith and Reynard, Textbook of Pharmacology, 1992, p868)
Approved
Matched Description: … (From Smith and Reynard, Textbook of Pharmacology, 1992, p868) …
Liotrix is a synthetically derived thyroid hormone replacement preparation. It consists of levothyroxine sodium (thyroxine, T4) and liothyronine sodium (triiodothyronine, T3) in a 4 to 1 ratio by weight. Liotrix was developed when it was believed that serum levels of both T4 and T3 were maintained by direct thyroidal secretion....
Approved
Matched Description: … and combination hormone replacement therapy generally offers no therapeutic advantage. ... It consists of levothyroxine sodium (thyroxine, T4) and liothyronine sodium (triiodothyronine, T3) in ... It is now known that the thyroid gland secretes approximately ten times more T4 than T3 and that 80% …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Approved
Experimental
Investigational
Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is...
Approved
Investigational
Matched Description: … Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Cytotoxic Antibiotics and Related Substances …
Droxidopa is a precursor of noradrenaline that is used in the treatment of Parkinsonism. It is approved for use in Japan and is currently in trials in the U.S. The racaemic form (dl-threo-3,4-dihydroxyphenylserine) has also been used, and has been investigated in the treatment of orthostatic hypotension. There is a...
Approved
Investigational
Matched Description: … associated with Parkinson's disease , pure autonomic failure, and multiple system atrophy, and is the ... It is approved for use in Japan and is currently in trials in the U.S. ... The racaemic form (dl-threo-3,4-dihydroxyphenylserine) has also been used, and has been investigated …
Matched Categories: … Epinephrine and similars ... Adrenergic and Dopaminergic Agents ... Amino Acids, Peptides, and Proteins …
Hydroxyamphetamine is a derivative of amphetamines. Hydroxyamphetamine is intended mainly as local eye drops for diagnostic purposes. It is indirect sympathomimetic agent which cause dilation of the eye pupil before diagnostic test. Among the minor side effects from its use are: change in color vision, difficulty seeing at night, dry...
Approved
Matched Description: … night, dry mouth, headache, increased sensitivity of eyes to sunlight, muscle stiffness or tightness and
Levomethamphetamine, the L-enantiomer of methamphetamine is a sympathomimetic vasoconstrictor used in some over-the-counter (OTC) nasal decongestant inhalers in the United States.
Approved
Elbasvir is a direct-acting antiviral medication used as part of combination therapy to treat chronic hepatitis C, an infectious liver disease caused by infection with hepatitis C virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in...
Approved
Matched Iupac: … 14-{2-[(2S)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl}-9-phenyl
Matched Description: … for genotype 1 and 97% and 100% for genotype 4 after 12 weeks of treatment. ... achieve a sustained virologic response (SVR), and have been shown to achieve a SVR between 94% and 97% ... Elbasvir is an inhibitor of NS5A, a protein essential for viral replication and virion assembly. …
Matched Categories: … elbasvir and grazoprevir …
Lifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome). It is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist that was discovered through the rational design process. The ophthalmic solution was approved in July, 2016 under the trade name Xiidra. It has...
Approved
Matched Description: … onset of action and well tolerated profile in both local and systemic setting [A18805]. ... It is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist ... It has shown to protect the corneal surface and alleviate the symptoms of dry eye syndrome with fast …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Gestrinone, also known as ethylnorgestrienone, is a synthetic steroid of the 19-nortestosterone group that is marketed in Europe, Australia, and Latin America, though not the United States or Canada, and is used primarily in the treatment of endometriosis. Gestrinone was developed in the early 1970s and was tested clinically as...
Approved
Matched Description: … in Europe and North America. ... Gestrinone was developed in the early 1970s and was tested clinically as a weekly oral contraceptive ... Without significant advantages over other oral contraceptives and with its high cost, gestrinone was …
Matched Categories: … Antigonadotropins and Similar Agents ... Genito Urinary System and Sex Hormones ... Sex Hormones and Modulators of the Genital System ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Naturally or synthetically produced steroid estrogens have a wide range of pharmaceutical uses ranging from hormonal contraception to the treatment of menopausal symptoms. Estetrol (E4) is a native estrogen occurring naturally during pregnancy, but can be synthesized from a plant source and used for contraception. It is more potent and...
Approved
Investigational
Matched Description: … a native estrogen occurring naturally during pregnancy, but can be synthesized from a plant source and ... [L33179] It is more potent and is safer than the synthetic estrogen ethinylestradiol (EE2) found in 97% ... [L33184] On April 15 2021, Mayne Pharma Group Limited and Mithra Pharmaceuticals were granted FDA …
Matched Categories: … drospirenone and estetrol ... Genito Urinary System and Sex Hormones ... Sex Hormones and Modulators of the Genital System ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Pnb has been used in trials studying the treatment of Pelvic Organ Prolapse.
Approved
Experimental
Investigational
Sparsentan is a dual antagonist of the endothelin type A receptor (ETAR) and the angiotensin II (Ang II) type 1 receptor (AT1R) with a similar affinity for both (9.3 nM for ETAR and 0.8 nM for AT1R).[A257330,L45300] Sparsentan is first in its class and orally active, and was created by...
Approved
Investigational
Matched Description: … [A257330,L45300] Sparsentan is first in its class and orally active, and was created by merging the structural ... Sparsentan is a dual antagonist of the endothelin type A receptor (ETAR) and the angiotensin ... [L45315] The use of sparsentan may cause hepatotoxicity and embryo-fetal toxicity.[L45300] …
Parthenolide has been used in trials studying the diagnostic of Allergic Contact Dermatitis.
Approved
Investigational
Fluticasone is a synthetic glucocorticoid available as 2 esters, DB08906 and DB00588[F4355,F4358,F4361,F4364][FDA Label]. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications[F4355,F4358,F4361,F4364][FDA Label]. DB00588 was first approved in 1990 and DB08906 was approved in 2007 .
Approved
Experimental
Matched Description: … [DB00588] was first approved in 1990[L5962] and [DB08906] was approved in 2007[L5965]. ... Fluticasone is a synthetic glucocorticoid available as 2 esters, [DB08906] and [DB00588][F4355,F4358, ... These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory …
Matched Categories: … formoterol and fluticasone ... salmeterol and fluticasone …
Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivosidenib was granted accelerated approval by the FDA...
Approved
Investigational
Matched Description: … and proliferation. ... IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth ... [A248750] Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
A cardioselective beta-1-adrenergic antagonist with no partial agonist activity.
Approved
Investigational
Matched Categories: … Antiglaucoma Preparations and Miotics …
Heart failure is a multifactorial condition that affects roughly 1-2% of the adult population. Often the result of long-term myocardial ischemia, cardiomyopathy, or other cardiac insults, heart failure results from an inability of the heart to perfuse peripheral tissues with sufficient oxygen and metabolites, resulting in complex systemic pathologies. Heart...
Approved
Matched Description: … and peripheral vasodilation in acute decongested heart failure. ... failure results from an inability of the heart to perfuse peripheral tissues with sufficient oxygen and ... cyclic adenosine monophosphate (cAMP) production, which affects the heart's contractile function and
Displaying drugs 376 - 400 of 14833 in total